Stelara Dosing for Psoriasis
Adults with moderate to severe plaque psoriasis start with subcutaneous injections of 45 mg or 90 mg at weeks 0 and 4, then 45 mg or 90 mg every 12 weeks. The 90 mg dose applies to patients over 100 kg; 45 mg for those 100 kg or less.[1]
Stelara Dosing for Ulcerative Colitis
Adults with moderately to severely active ulcerative colitis receive an intravenous (IV) induction dose of 260 mg (under 85 kg), 520 mg (85-85 kg), or 780 mg (over 120 kg) at week 0, followed by subcutaneous maintenance doses of 90 mg every 8 weeks starting at week 8.[1]
Key Differences in Regimens
Psoriasis uses only subcutaneous injections from the start, with induction at weeks 0 and 4, then every 12 weeks (45-90 mg). Ulcerative colitis begins with a weight-based IV infusion, then shifts to fixed 90 mg subcutaneous doses every 8 weeks—more frequent maintenance and an initial IV step not needed for psoriasis.[1]
Why the Dosing Schedules Differ
Psoriasis dosing prioritizes skin clearance with less frequent upkeep, while ulcerative colitis requires higher initial systemic exposure via IV for gut inflammation control, followed by tighter 8-week intervals to sustain remission.[1][2]
Patient Weight and Route Considerations
Weight drives psoriasis dose selection (45 mg vs 90 mg subcutaneous) but dictates exact IV induction mg for ulcerative colitis. All maintenance is subcutaneous for both, easing long-term administration.[1]
[1]: [Stelara Prescribing Information (Janssen)](https://www.stelara.com/sites/www Stelara/files/stelara-pi.pdf)
[2]: DrugPatentWatch.com - Stelara Patent and Indication Details